#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=There is little published literature considering the role of palliative radiotherapy in metastatic sarcoma , although it is recommended as a treatment option for palliation by both the UK bone and soft tissue sarcoma guidelines and the European Society of Medical Oncology ( ESMO ) guidelines .
2-1	14-19	There	_	_	_	_
2-2	20-22	is	_	_	_	_
2-3	23-29	little	abstract[2]	new[2]	_	_
2-4	30-39	published	abstract[2]	new[2]	_	_
2-5	40-50	literature	abstract[2]	new[2]	_	_
2-6	51-62	considering	abstract[2]	new[2]	_	_
2-7	63-66	the	abstract[2]|abstract[3]	new[2]|new[3]	coref	7-16[45_3]
2-8	67-71	role	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-9	72-74	of	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-10	75-85	palliative	abstract[2]|abstract[3]|abstract[4]	new[2]|new[3]|new[4]	ana	2-17[0_4]
2-11	86-98	radiotherapy	abstract[2]|abstract[3]|abstract[4]	new[2]|new[3]|new[4]	_	_
2-12	99-101	in	abstract[2]|abstract[3]|abstract[4]	new[2]|new[3]|new[4]	_	_
2-13	102-112	metastatic	abstract[2]|abstract[3]|abstract[4]|abstract[5]	new[2]|new[3]|new[4]|new[5]	_	_
2-14	113-120	sarcoma	abstract[2]|abstract[3]|abstract[4]|abstract[5]	new[2]|new[3]|new[4]|new[5]	_	_
2-15	121-122	,	_	_	_	_
2-16	123-131	although	_	_	_	_
2-17	132-134	it	abstract	giv	coref	3-19[25_0]
2-18	135-137	is	_	_	_	_
2-19	138-149	recommended	_	_	_	_
2-20	150-152	as	_	_	_	_
2-21	153-154	a	abstract[8]	new[8]	_	_
2-22	155-164	treatment	event|abstract[8]	new|new[8]	_	_
2-23	165-171	option	abstract[8]	new[8]	_	_
2-24	172-175	for	abstract[8]	new[8]	_	_
2-25	176-186	palliation	abstract[8]|abstract	new[8]|new	coref	7-19[46_0]
2-26	187-189	by	_	_	_	_
2-27	190-194	both	abstract[14]	new[14]	_	_
2-28	195-198	the	abstract[14]	new[14]	_	_
2-29	199-201	UK	person|abstract[14]	new|new[14]	_	_
2-30	202-206	bone	object|abstract[14]	new|new[14]	coref	9-5
2-31	207-210	and	abstract[14]	new[14]	_	_
2-32	211-215	soft	object[12]|abstract[14]	new[12]|new[14]	coref	9-1[55_12]
2-33	216-222	tissue	object[12]|abstract[14]	new[12]|new[14]	_	_
2-34	223-230	sarcoma	substance|abstract[14]	new|new[14]	coref	3-22
2-35	231-241	guidelines	abstract[14]	new[14]	_	_
2-36	242-245	and	_	_	_	_
2-37	246-249	the	organization[15]|abstract[18]	new[15]|new[18]	_	_
2-38	250-258	European	organization[15]|abstract[18]	new[15]|new[18]	_	_
2-39	259-266	Society	organization[15]|abstract[18]	new[15]|new[18]	_	_
2-40	267-269	of	organization[15]|abstract[18]	new[15]|new[18]	_	_
2-41	270-277	Medical	organization[15]|abstract[16]|abstract[18]	new[15]|new[16]|new[18]	appos	2-44[0_16]
2-42	278-286	Oncology	organization[15]|abstract[16]|abstract[18]	new[15]|new[16]|new[18]	_	_
2-43	287-288	(	abstract[18]	new[18]	_	_
2-44	289-293	ESMO	abstract|abstract[18]	giv|new[18]	ana	3-6
2-45	294-295	)	abstract[18]	new[18]	_	_
2-46	296-306	guidelines	abstract[18]	new[18]	_	_
2-47	307-308	.	_	_	_	_

#Text=To the authors ’ knowledge this is the largest retrospective study published to date reviewing the use of palliative radiotherapy for sarcoma .
3-1	309-311	To	_	_	_	_
3-2	312-315	the	abstract[20]	new[20]	_	_
3-3	316-323	authors	person[19]|abstract[20]	new[19]|new[20]	_	_
3-4	324-325	’	person[19]|abstract[20]	new[19]|new[20]	_	_
3-5	326-335	knowledge	abstract[20]	new[20]	_	_
3-6	336-340	this	abstract	giv	coref	3-8[22_0]
3-7	341-343	is	_	_	_	_
3-8	344-347	the	abstract[22]	giv[22]	coref	5-1[32_22]
3-9	348-355	largest	abstract[22]	giv[22]	_	_
3-10	356-369	retrospective	abstract[22]	giv[22]	_	_
3-11	370-375	study	abstract[22]	giv[22]	_	_
3-12	376-385	published	abstract[22]	giv[22]	_	_
3-13	386-388	to	abstract[22]	giv[22]	_	_
3-14	389-393	date	abstract[22]|time	giv[22]|new	_	_
3-15	394-403	reviewing	abstract[22]	giv[22]	_	_
3-16	404-407	the	abstract[22]|abstract[24]	giv[22]|new[24]	_	_
3-17	408-411	use	abstract[22]|abstract[24]	giv[22]|new[24]	_	_
3-18	412-414	of	abstract[22]|abstract[24]	giv[22]|new[24]	_	_
3-19	415-425	palliative	abstract[22]|abstract[24]|abstract[25]	giv[22]|new[24]|giv[25]	coref	4-5[28_25]
3-20	426-438	radiotherapy	abstract[22]|abstract[24]|abstract[25]	giv[22]|new[24]|giv[25]	_	_
3-21	439-442	for	abstract[22]|abstract[24]|abstract[25]	giv[22]|new[24]|giv[25]	_	_
3-22	443-450	sarcoma	abstract[22]|abstract[24]|abstract[25]|substance	giv[22]|new[24]|giv[25]|giv	coref	4-15[31_0]
3-23	451-452	.	_	_	_	_

#Text=The results confirm that palliative radiotherapy can successfully provide symptomatic benefit to patients with metastatic sarcoma .
4-1	453-456	The	abstract[27]	new[27]	coref	6-23[41_27]
4-2	457-464	results	abstract[27]	new[27]	_	_
4-3	465-472	confirm	_	_	_	_
4-4	473-477	that	_	_	_	_
4-5	478-488	palliative	abstract[28]	giv[28]	coref	7-13[0_28]
4-6	489-501	radiotherapy	abstract[28]	giv[28]	_	_
4-7	502-505	can	_	_	_	_
4-8	506-518	successfully	_	_	_	_
4-9	519-526	provide	_	_	_	_
4-10	527-538	symptomatic	abstract[29]	new[29]	coref	12-26[77_29]
4-11	539-546	benefit	abstract[29]	new[29]	_	_
4-12	547-549	to	_	_	_	_
4-13	550-558	patients	person[30]	new[30]	coref	14-10[88_30]
4-14	559-563	with	person[30]	new[30]	_	_
4-15	564-574	metastatic	person[30]|substance[31]	new[30]|giv[31]	coref	10-8[0_31]
4-16	575-582	sarcoma	person[30]|substance[31]	new[30]|giv[31]	_	_
4-17	583-584	.	_	_	_	_

#Text=This study is limited by being retrospective such that the assessment of symptomatic improvement could only be assessed from documentation in medical records .
5-1	585-589	This	abstract[32]	giv[32]	coref	8-4[53_32]
5-2	590-595	study	abstract[32]	giv[32]	_	_
5-3	596-598	is	_	_	_	_
5-4	599-606	limited	_	_	_	_
5-5	607-609	by	_	_	_	_
5-6	610-615	being	_	_	_	_
5-7	616-629	retrospective	_	_	_	_
5-8	630-634	such	_	_	_	_
5-9	635-639	that	_	_	_	_
5-10	640-643	the	abstract[33]	new[33]	_	_
5-11	644-654	assessment	abstract[33]	new[33]	_	_
5-12	655-657	of	abstract[33]	new[33]	_	_
5-13	658-669	symptomatic	abstract[33]|abstract[34]	new[33]|new[34]	coref	6-11[39_34]
5-14	670-681	improvement	abstract[33]|abstract[34]	new[33]|new[34]	_	_
5-15	682-687	could	_	_	_	_
5-16	688-692	only	_	_	_	_
5-17	693-695	be	_	_	_	_
5-18	696-704	assessed	_	_	_	_
5-19	705-709	from	_	_	_	_
5-20	710-723	documentation	abstract[35]	new[35]	ana	6-1[0_35]
5-21	724-726	in	abstract[35]	new[35]	_	_
5-22	727-734	medical	abstract[35]|abstract[36]	new[35]|new[36]	_	_
5-23	735-742	records	abstract[35]|abstract[36]	new[35]|new[36]	_	_
5-24	743-744	.	_	_	_	_

#Text=It was therefore not possible to quantify the amount of symptomatic improvement seen or indeed to be certain of the accuracy of the results .
6-1	745-747	It	abstract	giv	_	_
6-2	748-751	was	_	_	_	_
6-3	752-761	therefore	_	_	_	_
6-4	762-765	not	_	_	_	_
6-5	766-774	possible	_	_	_	_
6-6	775-777	to	_	_	_	_
6-7	778-786	quantify	_	_	_	_
6-8	787-790	the	abstract[38]	new[38]	_	_
6-9	791-797	amount	abstract[38]	new[38]	_	_
6-10	798-800	of	abstract[38]	new[38]	_	_
6-11	801-812	symptomatic	abstract[38]|abstract[39]	new[38]|giv[39]	coref	15-30[101_39]
6-12	813-824	improvement	abstract[38]|abstract[39]	new[38]|giv[39]	_	_
6-13	825-829	seen	abstract[38]|abstract[39]	new[38]|giv[39]	_	_
6-14	830-832	or	abstract[38]|abstract[39]	new[38]|giv[39]	_	_
6-15	833-839	indeed	abstract[38]|abstract[39]	new[38]|giv[39]	_	_
6-16	840-842	to	abstract[38]|abstract[39]	new[38]|giv[39]	_	_
6-17	843-845	be	abstract[38]|abstract[39]	new[38]|giv[39]	_	_
6-18	846-853	certain	abstract[38]|abstract[39]	new[38]|giv[39]	_	_
6-19	854-856	of	_	_	_	_
6-20	857-860	the	abstract[40]	new[40]	_	_
6-21	861-869	accuracy	abstract[40]	new[40]	_	_
6-22	870-872	of	abstract[40]	new[40]	_	_
6-23	873-876	the	abstract[40]|abstract[41]	new[40]|giv[41]	coref	17-1[112_41]
6-24	877-884	results	abstract[40]|abstract[41]	new[40]|giv[41]	_	_
6-25	885-886	.	_	_	_	_

#Text=The aim of this review , however , was to confirm that radiotherapy does have a role in the palliation of advanced sarcomas and to guide future prospective studies to gain more accurate evidence of the use of palliative radiotherapy in this setting .
7-1	887-890	The	abstract[42]	new[42]	_	_
7-2	891-894	aim	abstract[42]	new[42]	_	_
7-3	895-897	of	abstract[42]	new[42]	_	_
7-4	898-902	this	abstract[42]|event[43]	new[42]|new[43]	_	_
7-5	903-909	review	abstract[42]|event[43]	new[42]|new[43]	_	_
7-6	910-911	,	_	_	_	_
7-7	912-919	however	_	_	_	_
7-8	920-921	,	_	_	_	_
7-9	922-925	was	_	_	_	_
7-10	926-928	to	_	_	_	_
7-11	929-936	confirm	_	_	_	_
7-12	937-941	that	_	_	_	_
7-13	942-954	radiotherapy	abstract	giv	coref	7-39[51_0]
7-14	955-959	does	_	_	_	_
7-15	960-964	have	_	_	_	_
7-16	965-966	a	abstract[45]	giv[45]	_	_
7-17	967-971	role	abstract[45]	giv[45]	_	_
7-18	972-974	in	abstract[45]	giv[45]	_	_
7-19	975-978	the	abstract[45]|abstract[46]	giv[45]|giv[46]	coref	24-13[143_46]
7-20	979-989	palliation	abstract[45]|abstract[46]	giv[45]|giv[46]	_	_
7-21	990-992	of	abstract[45]|abstract[46]	giv[45]|giv[46]	_	_
7-22	993-1001	advanced	abstract[45]|abstract[46]|animal[47]	giv[45]|giv[46]|new[47]	coref	9-1[57_47]
7-23	1002-1010	sarcomas	abstract[45]|abstract[46]|animal[47]	giv[45]|giv[46]|new[47]	_	_
7-24	1011-1014	and	_	_	_	_
7-25	1015-1017	to	_	_	_	_
7-26	1018-1023	guide	_	_	_	_
7-27	1024-1030	future	abstract[48]	new[48]	_	_
7-28	1031-1042	prospective	abstract[48]	new[48]	_	_
7-29	1043-1050	studies	abstract[48]	new[48]	_	_
7-30	1051-1053	to	_	_	_	_
7-31	1054-1058	gain	_	_	_	_
7-32	1059-1063	more	abstract[49]	new[49]	coref	24-3[140_49]
7-33	1064-1072	accurate	abstract[49]	new[49]	_	_
7-34	1073-1081	evidence	abstract[49]	new[49]	_	_
7-35	1082-1084	of	abstract[49]	new[49]	_	_
7-36	1085-1088	the	abstract[49]|event[50]	new[49]|new[50]	_	_
7-37	1089-1092	use	abstract[49]|event[50]	new[49]|new[50]	_	_
7-38	1093-1095	of	abstract[49]|event[50]	new[49]|new[50]	_	_
7-39	1096-1106	palliative	abstract[49]|event[50]|abstract[51]	new[49]|new[50]|giv[51]	coref	11-10[68_51]
7-40	1107-1119	radiotherapy	abstract[49]|event[50]|abstract[51]	new[49]|new[50]|giv[51]	_	_
7-41	1120-1122	in	abstract[49]|event[50]|abstract[51]	new[49]|new[50]|giv[51]	_	_
7-42	1123-1127	this	abstract[49]|event[50]|abstract[51]|abstract[52]	new[49]|new[50]|giv[51]|new[52]	_	_
7-43	1128-1135	setting	abstract[49]|event[50]|abstract[51]|abstract[52]	new[49]|new[50]|giv[51]|new[52]	_	_
7-44	1136-1137	.	_	_	_	_

#Text=In addition , this study was limited by the heterogeneous population studied .
8-1	1138-1140	In	_	_	_	_
8-2	1141-1149	addition	_	_	_	_
8-3	1150-1151	,	_	_	_	_
8-4	1152-1156	this	abstract[53]	giv[53]	coref	15-1[93_53]
8-5	1157-1162	study	abstract[53]	giv[53]	_	_
8-6	1163-1166	was	_	_	_	_
8-7	1167-1174	limited	_	_	_	_
8-8	1175-1177	by	_	_	_	_
8-9	1178-1181	the	person[54]	new[54]	_	_
8-10	1182-1195	heterogeneous	person[54]	new[54]	_	_
8-11	1196-1206	population	person[54]	new[54]	_	_
8-12	1207-1214	studied	person[54]	new[54]	_	_
8-13	1215-1216	.	_	_	_	_

#Text=Both soft tissue and bone sarcomas of multiple types were included .
9-1	1217-1221	Both	object[55]|animal[57]	giv[55]|giv[57]	coref	16-2[0_57]
9-2	1222-1226	soft	object[55]|animal[57]	giv[55]|giv[57]	_	_
9-3	1227-1233	tissue	object[55]|animal[57]	giv[55]|giv[57]	_	_
9-4	1234-1237	and	animal[57]	giv[57]	_	_
9-5	1238-1242	bone	object|animal[57]	giv|giv[57]	coref	12-8
9-6	1243-1251	sarcomas	animal[57]	giv[57]	_	_
9-7	1252-1254	of	animal[57]	giv[57]	_	_
9-8	1255-1263	multiple	animal[57]|abstract[58]	giv[57]|new[58]	coref	11-13[70_58]
9-9	1264-1269	types	animal[57]|abstract[58]	giv[57]|new[58]	_	_
9-10	1270-1274	were	_	_	_	_
9-11	1275-1283	included	_	_	_	_
9-12	1284-1285	.	_	_	_	_

#Text=The radiobiology of the different subtypes of sarcoma has not been well studied , but it is accepted that these tumours tend to be relatively radio-resistant , with a high alpha beta ratio .
10-1	1286-1289	The	abstract[59]	new[59]	ana	10-16[0_59]
10-2	1290-1302	radiobiology	abstract[59]	new[59]	_	_
10-3	1303-1305	of	abstract[59]	new[59]	_	_
10-4	1306-1309	the	abstract[59]|abstract[60]	new[59]|new[60]	_	_
10-5	1310-1319	different	abstract[59]|abstract[60]	new[59]|new[60]	_	_
10-6	1320-1328	subtypes	abstract[59]|abstract[60]	new[59]|new[60]	_	_
10-7	1329-1331	of	abstract[59]|abstract[60]	new[59]|new[60]	_	_
10-8	1332-1339	sarcoma	abstract[59]|abstract[60]|substance	new[59]|new[60]|giv	coref	15-8[95_0]
10-9	1340-1343	has	_	_	_	_
10-10	1344-1347	not	_	_	_	_
10-11	1348-1352	been	_	_	_	_
10-12	1353-1357	well	_	_	_	_
10-13	1358-1365	studied	_	_	_	_
10-14	1366-1367	,	_	_	_	_
10-15	1368-1371	but	_	_	_	_
10-16	1372-1374	it	abstract	giv	_	_
10-17	1375-1377	is	_	_	_	_
10-18	1378-1386	accepted	_	_	_	_
10-19	1387-1391	that	_	_	_	_
10-20	1392-1397	these	animal[63]	new[63]	coref	25-18[160_63]
10-21	1398-1405	tumours	animal[63]	new[63]	_	_
10-22	1406-1410	tend	_	_	_	_
10-23	1411-1413	to	_	_	_	_
10-24	1414-1416	be	_	_	_	_
10-25	1417-1427	relatively	_	_	_	_
10-26	1428-1443	radio-resistant	_	_	_	_
10-27	1444-1445	,	_	_	_	_
10-28	1446-1450	with	_	_	_	_
10-29	1451-1452	a	abstract[65]	new[65]	_	_
10-30	1453-1457	high	abstract[65]	new[65]	_	_
10-31	1458-1463	alpha	person[64]|abstract[65]	new[64]|new[65]	_	_
10-32	1464-1468	beta	person[64]|abstract[65]	new[64]|new[65]	_	_
10-33	1469-1474	ratio	abstract[65]	new[65]	_	_
10-34	1475-1476	.	_	_	_	_

#Text=There have been several publications considering the role of palliative radiotherapy for other , more common solid tumour types .
11-1	1477-1482	There	_	_	_	_
11-2	1483-1487	have	_	_	_	_
11-3	1488-1492	been	_	_	_	_
11-4	1493-1500	several	organization[66]	new[66]	_	_
11-5	1501-1513	publications	organization[66]	new[66]	_	_
11-6	1514-1525	considering	organization[66]	new[66]	_	_
11-7	1526-1529	the	organization[66]|abstract[67]	new[66]|new[67]	_	_
11-8	1530-1534	role	organization[66]|abstract[67]	new[66]|new[67]	_	_
11-9	1535-1537	of	organization[66]|abstract[67]	new[66]|new[67]	_	_
11-10	1538-1548	palliative	organization[66]|abstract[67]|abstract[68]	new[66]|new[67]|giv[68]	coref	12-35[0_68]
11-11	1549-1561	radiotherapy	organization[66]|abstract[67]|abstract[68]	new[66]|new[67]|giv[68]	_	_
11-12	1562-1565	for	organization[66]|abstract[67]|abstract[68]	new[66]|new[67]|giv[68]	_	_
11-13	1566-1571	other	organization[66]|abstract[67]|abstract[68]|abstract[70]	new[66]|new[67]|giv[68]|giv[70]	_	_
11-14	1572-1573	,	organization[66]|abstract[67]|abstract[68]|abstract[70]	new[66]|new[67]|giv[68]|giv[70]	_	_
11-15	1574-1578	more	organization[66]|abstract[67]|abstract[68]|abstract[70]	new[66]|new[67]|giv[68]|giv[70]	_	_
11-16	1579-1585	common	organization[66]|abstract[67]|abstract[68]|abstract[70]	new[66]|new[67]|giv[68]|giv[70]	_	_
11-17	1586-1591	solid	organization[66]|abstract[67]|abstract[68]|abstract[70]	new[66]|new[67]|giv[68]|giv[70]	_	_
11-18	1592-1598	tumour	organization[66]|abstract[67]|abstract[68]|abstract|abstract[70]	new[66]|new[67]|giv[68]|new|giv[70]	coref	12-16
11-19	1599-1604	types	organization[66]|abstract[67]|abstract[68]|abstract[70]	new[66]|new[67]|giv[68]|giv[70]	_	_
11-20	1605-1606	.	_	_	_	_

#Text=A meta-analysis has shown that when treating bone metastases from a number of different primary tumour sites and histology ’s , there appears to be little short-term symptomatic benefit in a fractionated course of radiotherapy , compared to a single fraction .
12-1	1607-1608	A	abstract[71]	new[71]	_	_
12-2	1609-1622	meta-analysis	abstract[71]	new[71]	_	_
12-3	1623-1626	has	_	_	_	_
12-4	1627-1632	shown	_	_	_	_
12-5	1633-1637	that	_	_	_	_
12-6	1638-1642	when	_	_	_	_
12-7	1643-1651	treating	_	_	_	_
12-8	1652-1656	bone	object|object[73]	giv|new[73]	coref|coref	13-16|13-16[86_73]
12-9	1657-1667	metastases	object[73]	new[73]	_	_
12-10	1668-1672	from	_	_	_	_
12-11	1673-1674	a	place[75]	new[75]	_	_
12-12	1675-1681	number	place[75]	new[75]	_	_
12-13	1682-1684	of	place[75]	new[75]	_	_
12-14	1685-1694	different	place[75]	new[75]	_	_
12-15	1695-1702	primary	place[75]	new[75]	_	_
12-16	1703-1709	tumour	abstract|place[75]	giv|new[75]	_	_
12-17	1710-1715	sites	place[75]	new[75]	_	_
12-18	1716-1719	and	_	_	_	_
12-19	1720-1729	histology	person[76]	new[76]	_	_
12-20	1730-1732	’s	person[76]	new[76]	_	_
12-21	1733-1734	,	_	_	_	_
12-22	1735-1740	there	_	_	_	_
12-23	1741-1748	appears	_	_	_	_
12-24	1749-1751	to	_	_	_	_
12-25	1752-1754	be	_	_	_	_
12-26	1755-1761	little	abstract[77]	giv[77]	coref	16-27[111_77]
12-27	1762-1772	short-term	abstract[77]	giv[77]	_	_
12-28	1773-1784	symptomatic	abstract[77]	giv[77]	_	_
12-29	1785-1792	benefit	abstract[77]	giv[77]	_	_
12-30	1793-1795	in	abstract[77]	giv[77]	_	_
12-31	1796-1797	a	abstract[77]|abstract[78]	giv[77]|new[78]	_	_
12-32	1798-1810	fractionated	abstract[77]|abstract[78]	giv[77]|new[78]	_	_
12-33	1811-1817	course	abstract[77]|abstract[78]	giv[77]|new[78]	_	_
12-34	1818-1820	of	abstract[77]|abstract[78]	giv[77]|new[78]	_	_
12-35	1821-1833	radiotherapy	abstract[77]|abstract[78]|abstract	giv[77]|new[78]|giv	coref	14-17[90_0]
12-36	1834-1835	,	_	_	_	_
12-37	1836-1844	compared	_	_	_	_
12-38	1845-1847	to	_	_	_	_
12-39	1848-1849	a	abstract[80]	new[80]	coref	13-8[83_80]
12-40	1850-1856	single	abstract[80]	new[80]	_	_
12-41	1857-1865	fraction	abstract[80]	new[80]	_	_
12-42	1866-1867	.	_	_	_	_

#Text=Most oncologists therefore advocate the use of a single fraction to control pain secondary to bone metastases .
13-1	1868-1872	Most	person[81]	new[81]	_	_
13-2	1873-1884	oncologists	person[81]	new[81]	_	_
13-3	1885-1894	therefore	_	_	_	_
13-4	1895-1903	advocate	_	_	_	_
13-5	1904-1907	the	event[82]	new[82]	_	_
13-6	1908-1911	use	event[82]	new[82]	_	_
13-7	1912-1914	of	event[82]	new[82]	_	_
13-8	1915-1916	a	event[82]|abstract[83]	new[82]|giv[83]	coref	14-28[92_83]
13-9	1917-1923	single	event[82]|abstract[83]	new[82]|giv[83]	_	_
13-10	1924-1932	fraction	event[82]|abstract[83]	new[82]|giv[83]	_	_
13-11	1933-1935	to	_	_	_	_
13-12	1936-1943	control	_	_	_	_
13-13	1944-1948	pain	abstract[84]	new[84]	coref	27-38[0_84]
13-14	1949-1958	secondary	abstract[84]	new[84]	_	_
13-15	1959-1961	to	_	_	_	_
13-16	1962-1966	bone	object|object[86]	giv|giv[86]	_	_
13-17	1967-1977	metastases	object[86]	giv[86]	_	_
13-18	1978-1979	.	_	_	_	_

#Text=With longer follow-up , however , it seems that patients treated with a fractionated course of palliative radiotherapy are less likely to need retreatment than those given a single fraction .
14-1	1980-1984	With	_	_	_	_
14-2	1985-1991	longer	event[87]	new[87]	_	_
14-3	1992-2001	follow-up	event[87]	new[87]	_	_
14-4	2002-2003	,	_	_	_	_
14-5	2004-2011	however	_	_	_	_
14-6	2012-2013	,	_	_	_	_
14-7	2014-2016	it	_	_	_	_
14-8	2017-2022	seems	_	_	_	_
14-9	2023-2027	that	_	_	_	_
14-10	2028-2036	patients	person[88]	giv[88]	coref	15-5[94_88]
14-11	2037-2044	treated	person[88]	giv[88]	_	_
14-12	2045-2049	with	person[88]	giv[88]	_	_
14-13	2050-2051	a	person[88]|abstract[89]	giv[88]|new[89]	_	_
14-14	2052-2064	fractionated	person[88]|abstract[89]	giv[88]|new[89]	_	_
14-15	2065-2071	course	person[88]|abstract[89]	giv[88]|new[89]	_	_
14-16	2072-2074	of	person[88]|abstract[89]	giv[88]|new[89]	_	_
14-17	2075-2085	palliative	person[88]|abstract[89]|abstract[90]	giv[88]|new[89]|giv[90]	coref	15-13[96_90]
14-18	2086-2098	radiotherapy	person[88]|abstract[89]|abstract[90]	giv[88]|new[89]|giv[90]	_	_
14-19	2099-2102	are	_	_	_	_
14-20	2103-2107	less	_	_	_	_
14-21	2108-2114	likely	_	_	_	_
14-22	2115-2117	to	_	_	_	_
14-23	2118-2122	need	_	_	_	_
14-24	2123-2134	retreatment	event	new	coref	26-52
14-25	2135-2139	than	_	_	_	_
14-26	2140-2145	those	_	_	_	_
14-27	2146-2151	given	_	_	_	_
14-28	2152-2153	a	abstract[92]	giv[92]	coref	16-15[109_92]
14-29	2154-2160	single	abstract[92]	giv[92]	_	_
14-30	2161-2169	fraction	abstract[92]	giv[92]	_	_
14-31	2170-2171	.	_	_	_	_

#Text=This study demonstrates that selected patients with advanced sarcoma can benefit from palliative radiotherapy provided their prognosis is long enough for the benefits from radiotherapy , in terms of symptomatic improvement , to outweigh the inconvenience of undergoing radiotherapy and the associated side effects that they may suffer .
15-1	2172-2176	This	abstract[93]	giv[93]	_	_
15-2	2177-2182	study	abstract[93]	giv[93]	_	_
15-3	2183-2195	demonstrates	_	_	_	_
15-4	2196-2200	that	_	_	_	_
15-5	2201-2209	selected	person[94]	giv[94]	ana	15-16[0_94]
15-6	2210-2218	patients	person[94]	giv[94]	_	_
15-7	2219-2223	with	person[94]	giv[94]	_	_
15-8	2224-2232	advanced	person[94]|substance[95]	giv[94]|giv[95]	coref	24-15[0_95]
15-9	2233-2240	sarcoma	person[94]|substance[95]	giv[94]|giv[95]	_	_
15-10	2241-2244	can	_	_	_	_
15-11	2245-2252	benefit	abstract	new	coref|none	15-22[99_0]|15-11[0_99]
15-12	2253-2257	from	_	_	_	_
15-13	2258-2268	palliative	abstract[96]	giv[96]	coref	15-25[0_96]
15-14	2269-2281	radiotherapy	abstract[96]	giv[96]	_	_
15-15	2282-2290	provided	_	_	_	_
15-16	2291-2296	their	person|abstract[98]	giv|new[98]	ana|coref	15-46|26-36[0_98]
15-17	2297-2306	prognosis	abstract[98]	new[98]	_	_
15-18	2307-2309	is	_	_	_	_
15-19	2310-2314	long	_	_	_	_
15-20	2315-2321	enough	_	_	_	_
15-21	2322-2325	for	_	_	_	_
15-22	2326-2329	the	abstract[99]	new[99]	_	_
15-23	2330-2338	benefits	abstract[99]	new[99]	_	_
15-24	2339-2343	from	abstract[99]	new[99]	_	_
15-25	2344-2356	radiotherapy	abstract[99]|abstract	new[99]|giv	coref	15-39
15-26	2357-2358	,	abstract[99]	new[99]	_	_
15-27	2359-2361	in	abstract[99]	new[99]	_	_
15-28	2362-2367	terms	abstract[99]	new[99]	_	_
15-29	2368-2370	of	abstract[99]	new[99]	_	_
15-30	2371-2382	symptomatic	abstract[99]|abstract[101]	new[99]|giv[101]	_	_
15-31	2383-2394	improvement	abstract[99]|abstract[101]	new[99]|giv[101]	_	_
15-32	2395-2396	,	_	_	_	_
15-33	2397-2399	to	_	_	_	_
15-34	2400-2408	outweigh	_	_	_	_
15-35	2409-2412	the	abstract[102]	new[102]	_	_
15-36	2413-2426	inconvenience	abstract[102]	new[102]	_	_
15-37	2427-2429	of	abstract[102]	new[102]	_	_
15-38	2430-2440	undergoing	abstract[102]	new[102]	_	_
15-39	2441-2453	radiotherapy	abstract[102]|abstract	new[102]|giv	ana	16-10
15-40	2454-2457	and	_	_	_	_
15-41	2458-2461	the	abstract[105]	new[105]	_	_
15-42	2462-2472	associated	abstract[105]	new[105]	_	_
15-43	2473-2477	side	abstract|abstract[105]	new|new[105]	_	_
15-44	2478-2485	effects	abstract[105]	new[105]	_	_
15-45	2486-2490	that	abstract[105]	new[105]	_	_
15-46	2491-2495	they	abstract[105]|person	new[105]|giv	coref	23-9[132_0]
15-47	2496-2499	may	abstract[105]	new[105]	_	_
15-48	2500-2506	suffer	abstract[105]	new[105]	_	_
15-49	2507-2508	.	_	_	_	_

#Text=As sarcomas are felt to be intrinsically radio-resistant , it can be hypothesized that a single fraction of palliative radiotherapy may not be sufficient to offer adequate symptomatic benefit .
16-1	2509-2511	As	_	_	_	_
16-2	2512-2520	sarcomas	animal	giv	_	_
16-3	2521-2524	are	_	_	_	_
16-4	2525-2529	felt	_	_	_	_
16-5	2530-2532	to	_	_	_	_
16-6	2533-2535	be	_	_	_	_
16-7	2536-2549	intrinsically	_	_	_	_
16-8	2550-2565	radio-resistant	_	_	_	_
16-9	2566-2567	,	_	_	_	_
16-10	2568-2570	it	abstract	giv	coref	16-19[110_0]
16-11	2571-2574	can	_	_	_	_
16-12	2575-2577	be	_	_	_	_
16-13	2578-2590	hypothesized	_	_	_	_
16-14	2591-2595	that	_	_	_	_
16-15	2596-2597	a	abstract[109]	giv[109]	coref	25-2[156_109]
16-16	2598-2604	single	abstract[109]	giv[109]	_	_
16-17	2605-2613	fraction	abstract[109]	giv[109]	_	_
16-18	2614-2616	of	abstract[109]	giv[109]	_	_
16-19	2617-2627	palliative	abstract[109]|abstract[110]	giv[109]|giv[110]	coref	20-21[126_110]
16-20	2628-2640	radiotherapy	abstract[109]|abstract[110]	giv[109]|giv[110]	_	_
16-21	2641-2644	may	_	_	_	_
16-22	2645-2648	not	_	_	_	_
16-23	2649-2651	be	_	_	_	_
16-24	2652-2662	sufficient	_	_	_	_
16-25	2663-2665	to	_	_	_	_
16-26	2666-2671	offer	_	_	_	_
16-27	2672-2680	adequate	abstract[111]	giv[111]	coref	26-16[170_111]
16-28	2681-2692	symptomatic	abstract[111]	giv[111]	_	_
16-29	2693-2700	benefit	abstract[111]	giv[111]	_	_
16-30	2701-2702	.	_	_	_	_

#Text=The results presented here suggest a higher symptomatic response rate with a biological effective dose ( BED ) of 50 or greater .
17-1	2703-2706	The	abstract[112]	giv[112]	_	_
17-2	2707-2714	results	abstract[112]	giv[112]	_	_
17-3	2715-2724	presented	abstract[112]	giv[112]	_	_
17-4	2725-2729	here	abstract[112]	giv[112]	_	_
17-5	2730-2737	suggest	_	_	_	_
17-6	2738-2739	a	abstract[114]	new[114]	coref	19-6[121_114]
17-7	2740-2746	higher	abstract[114]	new[114]	_	_
17-8	2747-2758	symptomatic	abstract[114]	new[114]	_	_
17-9	2759-2767	response	abstract|abstract[114]	new|new[114]	coref	19-6
17-10	2768-2772	rate	abstract[114]	new[114]	_	_
17-11	2773-2777	with	abstract[114]	new[114]	_	_
17-12	2778-2779	a	abstract[114]|abstract[115]	new[114]|new[115]	appos	17-17[0_115]
17-13	2780-2790	biological	abstract[114]|abstract[115]	new[114]|new[115]	_	_
17-14	2791-2800	effective	abstract[114]|abstract[115]	new[114]|new[115]	_	_
17-15	2801-2805	dose	abstract[114]|abstract[115]	new[114]|new[115]	_	_
17-16	2806-2807	(	_	_	_	_
17-17	2808-2811	BED	abstract	giv	coref	19-10
17-18	2812-2813	)	_	_	_	_
17-19	2814-2816	of	_	_	_	_
17-20	2817-2819	50	abstract	new	_	_
17-21	2820-2822	or	_	_	_	_
17-22	2823-2830	greater	_	_	_	_
17-23	2831-2832	.	_	_	_	_

#Text=Figure 3
18-1	2833-2839	Figure	abstract[118]	new[118]	coref	22-1[130_118]
18-2	2840-2841	3	abstract[118]	new[118]	_	_

#Text=b demonstrates an increase in response rate with increasing BED up to 50 Gy4 .
19-1	2842-2843	b	_	_	_	_
19-2	2844-2856	demonstrates	_	_	_	_
19-3	2857-2859	an	event[119]	new[119]	_	_
19-4	2860-2868	increase	event[119]	new[119]	_	_
19-5	2869-2871	in	event[119]	new[119]	_	_
19-6	2872-2880	response	event[119]|abstract|abstract[121]	new[119]|giv|giv[121]	coref	20-4[124_0]
19-7	2881-2885	rate	event[119]|abstract[121]	new[119]|giv[121]	_	_
19-8	2886-2890	with	_	_	_	_
19-9	2891-2901	increasing	_	_	_	_
19-10	2902-2905	BED	abstract	giv	coref	23-11[133_0]
19-11	2906-2908	up	_	_	_	_
19-12	2909-2911	to	_	_	_	_
19-13	2912-2914	50	_	_	_	_
19-14	2915-2918	Gy4	_	_	_	_
19-15	2919-2920	.	_	_	_	_

#Text=Beyond this point the response is maintained but does not appear to increase further , suggesting very high doses of palliative radiotherapy may not be necessary to achieve a good symptomatic response in this patient group .
20-1	2921-2927	Beyond	_	_	_	_
20-2	2928-2932	this	abstract[123]	new[123]	_	_
20-3	2933-2938	point	abstract[123]	new[123]	_	_
20-4	2939-2942	the	abstract[124]	giv[124]	coref	20-29[127_124]
20-5	2943-2951	response	abstract[124]	giv[124]	_	_
20-6	2952-2954	is	_	_	_	_
20-7	2955-2965	maintained	_	_	_	_
20-8	2966-2969	but	_	_	_	_
20-9	2970-2974	does	_	_	_	_
20-10	2975-2978	not	_	_	_	_
20-11	2979-2985	appear	_	_	_	_
20-12	2986-2988	to	_	_	_	_
20-13	2989-2997	increase	_	_	_	_
20-14	2998-3005	further	_	_	_	_
20-15	3006-3007	,	_	_	_	_
20-16	3008-3018	suggesting	_	_	_	_
20-17	3019-3023	very	abstract[125]	new[125]	_	_
20-18	3024-3028	high	abstract[125]	new[125]	_	_
20-19	3029-3034	doses	abstract[125]	new[125]	_	_
20-20	3035-3037	of	abstract[125]	new[125]	_	_
20-21	3038-3048	palliative	abstract[125]|abstract[126]	new[125]|giv[126]	coref	24-11[0_126]
20-22	3049-3061	radiotherapy	abstract[125]|abstract[126]	new[125]|giv[126]	_	_
20-23	3062-3065	may	_	_	_	_
20-24	3066-3069	not	_	_	_	_
20-25	3070-3072	be	_	_	_	_
20-26	3073-3082	necessary	_	_	_	_
20-27	3083-3085	to	_	_	_	_
20-28	3086-3093	achieve	_	_	_	_
20-29	3094-3095	a	abstract[127]	giv[127]	coref	23-3[131_127]
20-30	3096-3100	good	abstract[127]	giv[127]	_	_
20-31	3101-3112	symptomatic	abstract[127]	giv[127]	_	_
20-32	3113-3121	response	abstract[127]	giv[127]	_	_
20-33	3122-3124	in	abstract[127]	giv[127]	_	_
20-34	3125-3129	this	abstract[127]|person[128]	giv[127]|new[128]	_	_
20-35	3130-3137	patient	abstract[127]|person[128]	giv[127]|new[128]	_	_
20-36	3138-3143	group	abstract[127]|person[128]	giv[127]|new[128]	_	_
20-37	3144-3145	.	_	_	_	_

#Text=The one apparent outlier in
21-1	3146-3149	The	person[129]	new[129]	coref	23-23[137_129]
21-2	3150-3153	one	person[129]	new[129]	_	_
21-3	3154-3162	apparent	person[129]	new[129]	_	_
21-4	3163-3170	outlier	person[129]	new[129]	_	_
21-5	3171-3173	in	person[129]	new[129]	_	_

#Text=Figure 3
22-1	3174-3180	Figure	abstract[130]	giv[130]	_	_
22-2	3181-3182	3	abstract[130]	giv[130]	_	_

#Text=b is the 100 % symptomatic response in patients receiving a BED of 30 – 39.9 , this is likely to be an outlier as there was only one patient in this group .
23-1	3183-3184	b	_	_	_	_
23-2	3185-3187	is	_	_	_	_
23-3	3188-3191	the	abstract[131]	giv[131]	_	_
23-4	3192-3195	100	abstract[131]	giv[131]	_	_
23-5	3196-3197	%	abstract[131]	giv[131]	_	_
23-6	3198-3209	symptomatic	abstract[131]	giv[131]	_	_
23-7	3210-3218	response	abstract[131]	giv[131]	_	_
23-8	3219-3221	in	abstract[131]	giv[131]	_	_
23-9	3222-3230	patients	abstract[131]|person[132]	giv[131]|giv[132]	coref	26-29[173_132]
23-10	3231-3240	receiving	abstract[131]|person[132]	giv[131]|giv[132]	_	_
23-11	3241-3242	a	abstract[131]|person[132]|abstract[133]	giv[131]|giv[132]|giv[133]	coref	24-22[0_133]
23-12	3243-3246	BED	abstract[131]|person[132]|abstract[133]	giv[131]|giv[132]|giv[133]	_	_
23-13	3247-3249	of	abstract[131]|person[132]|abstract[133]	giv[131]|giv[132]|giv[133]	_	_
23-14	3250-3252	30	abstract[131]|person[132]|abstract[133]|time[134]	giv[131]|giv[132]|giv[133]|new[134]	_	_
23-15	3253-3254	–	abstract[131]|person[132]|abstract[133]|time[134]	giv[131]|giv[132]|giv[133]|new[134]	_	_
23-16	3255-3259	39.9	abstract[131]|person[132]|abstract[133]|time[134]|abstract	giv[131]|giv[132]|giv[133]|new[134]|new	ana	23-18
23-17	3260-3261	,	_	_	_	_
23-18	3262-3266	this	abstract	giv	_	_
23-19	3267-3269	is	_	_	_	_
23-20	3270-3276	likely	_	_	_	_
23-21	3277-3279	to	_	_	_	_
23-22	3280-3282	be	_	_	_	_
23-23	3283-3285	an	person[137]	giv[137]	_	_
23-24	3286-3293	outlier	person[137]	giv[137]	_	_
23-25	3294-3296	as	_	_	_	_
23-26	3297-3302	there	_	_	_	_
23-27	3303-3306	was	_	_	_	_
23-28	3307-3311	only	person[138]	giv[138]	_	_
23-29	3312-3315	one	person[138]	giv[138]	_	_
23-30	3316-3323	patient	person[138]	giv[138]	_	_
23-31	3324-3326	in	person[138]	giv[138]	_	_
23-32	3327-3331	this	person[138]|animal[139]	giv[138]|new[139]	_	_
23-33	3332-3337	group	person[138]|animal[139]	giv[138]|new[139]	_	_
23-34	3338-3339	.	_	_	_	_

#Text=Because of the limited evidence available in the use of radiotherapy for palliation in sarcoma the Royal College of Radiologists Radiotherapy dose fractionation guidance ( 3rd edition ) recommends several different dose fractionation schedules ( Table 5 ) .
24-1	3340-3347	Because	_	_	_	_
24-2	3348-3350	of	_	_	_	_
24-3	3351-3354	the	abstract[140]	giv[140]	_	_
24-4	3355-3362	limited	abstract[140]	giv[140]	_	_
24-5	3363-3371	evidence	abstract[140]	giv[140]	_	_
24-6	3372-3381	available	abstract[140]	giv[140]	_	_
24-7	3382-3384	in	_	_	_	_
24-8	3385-3388	the	abstract[141]	new[141]	_	_
24-9	3389-3392	use	abstract[141]	new[141]	_	_
24-10	3393-3395	of	abstract[141]	new[141]	_	_
24-11	3396-3408	radiotherapy	abstract[141]|abstract	new[141]|giv	coref	24-21
24-12	3409-3412	for	abstract[141]	new[141]	_	_
24-13	3413-3423	palliation	abstract[141]|abstract[143]	new[141]|giv[143]	_	_
24-14	3424-3426	in	abstract[141]|abstract[143]	new[141]|giv[143]	_	_
24-15	3427-3434	sarcoma	abstract[141]|abstract[143]|substance	new[141]|giv[143]|giv	coref	27-14
24-16	3435-3438	the	abstract[150]	new[150]	appos	24-26[151_150]
24-17	3439-3444	Royal	organization[145]|abstract[150]	new[145]|new[150]	_	_
24-18	3445-3452	College	organization[145]|abstract[150]	new[145]|new[150]	_	_
24-19	3453-3455	of	organization[145]|abstract[150]	new[145]|new[150]	_	_
24-20	3456-3468	Radiologists	organization[145]|abstract|abstract[150]	new[145]|new|new[150]	coref	33-30
24-21	3469-3481	Radiotherapy	abstract|abstract[150]	giv|new[150]	coref	26-12
24-22	3482-3486	dose	abstract|object[149]|abstract[150]	giv|new[149]|new[150]	coref|coref	24-32|24-32[153_149]
24-23	3487-3500	fractionation	object[149]|abstract[150]	new[149]|new[150]	_	_
24-24	3501-3509	guidance	abstract[150]	new[150]	_	_
24-25	3510-3511	(	_	_	_	_
24-26	3512-3515	3rd	abstract[151]	giv[151]	_	_
24-27	3516-3523	edition	abstract[151]	giv[151]	_	_
24-28	3524-3525	)	_	_	_	_
24-29	3526-3536	recommends	_	_	_	_
24-30	3537-3544	several	abstract[154]	new[154]	coref	25-12[159_154]
24-31	3545-3554	different	abstract[154]	new[154]	_	_
24-32	3555-3559	dose	abstract|object[153]|abstract[154]	giv|giv[153]|new[154]	coref|coref	25-25|25-26[0_153]
24-33	3560-3573	fractionation	object[153]|abstract[154]	giv[153]|new[154]	_	_
24-34	3574-3583	schedules	abstract[154]	new[154]	_	_
24-35	3584-3585	(	_	_	_	_
24-36	3586-3591	Table	_	_	_	_
24-37	3592-3593	5	_	_	_	_
24-38	3594-3595	)	_	_	_	_
24-39	3596-3597	.	_	_	_	_

#Text=Excluding 8 Gy single fraction and 20 Gy in 5 fractions which are commonly used schedules for all solid tumours ; the remaining recommended dose fractionation schedules all have a BED of greater than 50 Gy4 .
25-1	3598-3607	Excluding	_	_	_	_
25-2	3608-3609	8	abstract[155]|abstract[156]	new[155]|giv[156]	_	_
25-3	3610-3612	Gy	abstract[155]|abstract[156]	new[155]|giv[156]	_	_
25-4	3613-3619	single	abstract[156]	giv[156]	_	_
25-5	3620-3628	fraction	abstract[156]	giv[156]	_	_
25-6	3629-3632	and	_	_	_	_
25-7	3633-3635	20	abstract[157]	new[157]	_	_
25-8	3636-3638	Gy	abstract[157]	new[157]	_	_
25-9	3639-3641	in	abstract[157]	new[157]	_	_
25-10	3642-3643	5	abstract[157]|abstract[158]	new[157]|new[158]	_	_
25-11	3644-3653	fractions	abstract[157]|abstract[158]	new[157]|new[158]	_	_
25-12	3654-3659	which	abstract[157]|abstract[159]	new[157]|giv[159]	coref	25-22[163_159]
25-13	3660-3663	are	abstract[157]|abstract[159]	new[157]|giv[159]	_	_
25-14	3664-3672	commonly	abstract[157]|abstract[159]	new[157]|giv[159]	_	_
25-15	3673-3677	used	abstract[157]|abstract[159]	new[157]|giv[159]	_	_
25-16	3678-3687	schedules	abstract[157]|abstract[159]	new[157]|giv[159]	_	_
25-17	3688-3691	for	abstract[157]|abstract[159]	new[157]|giv[159]	_	_
25-18	3692-3695	all	abstract[157]|abstract[159]|animal[160]	new[157]|giv[159]|giv[160]	_	_
25-19	3696-3701	solid	abstract[157]|abstract[159]|animal[160]	new[157]|giv[159]|giv[160]	_	_
25-20	3702-3709	tumours	abstract[157]|abstract[159]|animal[160]	new[157]|giv[159]|giv[160]	_	_
25-21	3710-3711	;	_	_	_	_
25-22	3712-3715	the	abstract[163]	giv[163]	coref	32-7[219_163]
25-23	3716-3725	remaining	abstract[163]	giv[163]	_	_
25-24	3726-3737	recommended	abstract[163]	giv[163]	_	_
25-25	3738-3742	dose	abstract|abstract[163]	giv|giv[163]	coref	28-16[198_0]
25-26	3743-3756	fractionation	object|abstract[163]	giv|giv[163]	coref	31-32
25-27	3757-3766	schedules	abstract[163]	giv[163]	_	_
25-28	3767-3770	all	_	_	_	_
25-29	3771-3775	have	_	_	_	_
25-30	3776-3777	a	abstract[164]	new[164]	_	_
25-31	3778-3781	BED	abstract[164]	new[164]	_	_
25-32	3782-3784	of	abstract[164]	new[164]	_	_
25-33	3785-3792	greater	abstract[164]|abstract[165]	new[164]|new[165]	_	_
25-34	3793-3797	than	abstract[164]|abstract[165]	new[164]|new[165]	_	_
25-35	3798-3800	50	abstract[164]|abstract[165]	new[164]|new[165]	_	_
25-36	3801-3804	Gy4	abstract[164]|abstract[165]	new[164]|new[165]	_	_
25-37	3805-3806	.	_	_	_	_

#Text=Although this case series has demonstrated that very high doses of radiotherapy may not provide additional short-term symptomatic benefit , longer courses of radiotherapy may be considered in patients with a good performance status and prognosis in an attempt to provide a longer period of symptomatic benefit without the need for retreatment .
26-1	3807-3815	Although	_	_	_	_
26-2	3816-3820	this	abstract[167]	new[167]	coref	27-1[183_167]
26-3	3821-3825	case	person|abstract[167]	new|new[167]	coref	27-4
26-4	3826-3832	series	abstract[167]	new[167]	_	_
26-5	3833-3836	has	_	_	_	_
26-6	3837-3849	demonstrated	_	_	_	_
26-7	3850-3854	that	_	_	_	_
26-8	3855-3859	very	substance[168]	new[168]	_	_
26-9	3860-3864	high	substance[168]	new[168]	_	_
26-10	3865-3870	doses	substance[168]	new[168]	_	_
26-11	3871-3873	of	substance[168]	new[168]	_	_
26-12	3874-3886	radiotherapy	substance[168]|abstract	new[168]|giv	coref	26-24
26-13	3887-3890	may	_	_	_	_
26-14	3891-3894	not	_	_	_	_
26-15	3895-3902	provide	_	_	_	_
26-16	3903-3913	additional	abstract[170]	giv[170]	coref	26-46[179_170]
26-17	3914-3924	short-term	abstract[170]	giv[170]	_	_
26-18	3925-3936	symptomatic	abstract[170]	giv[170]	_	_
26-19	3937-3944	benefit	abstract[170]	giv[170]	_	_
26-20	3945-3946	,	_	_	_	_
26-21	3947-3953	longer	place[171]	new[171]	_	_
26-22	3954-3961	courses	place[171]	new[171]	_	_
26-23	3962-3964	of	place[171]	new[171]	_	_
26-24	3965-3977	radiotherapy	place[171]|abstract	new[171]|giv	coref	27-11[185_0]
26-25	3978-3981	may	_	_	_	_
26-26	3982-3984	be	_	_	_	_
26-27	3985-3995	considered	_	_	_	_
26-28	3996-3998	in	_	_	_	_
26-29	3999-4007	patients	person[173]	giv[173]	coref	27-7[184_173]
26-30	4008-4012	with	person[173]	giv[173]	_	_
26-31	4013-4014	a	person[173]|abstract[175]	giv[173]|new[175]	_	_
26-32	4015-4019	good	person[173]|abstract[175]	giv[173]|new[175]	_	_
26-33	4020-4031	performance	person[173]|abstract|abstract[175]	giv[173]|new|new[175]	_	_
26-34	4032-4038	status	person[173]|abstract[175]	giv[173]|new[175]	_	_
26-35	4039-4042	and	person[173]	giv[173]	_	_
26-36	4043-4052	prognosis	person[173]|abstract	giv[173]|giv	_	_
26-37	4053-4055	in	_	_	_	_
26-38	4056-4058	an	event[177]	new[177]	_	_
26-39	4059-4066	attempt	event[177]	new[177]	_	_
26-40	4067-4069	to	event[177]	new[177]	_	_
26-41	4070-4077	provide	event[177]	new[177]	_	_
26-42	4078-4079	a	event[177]|time[178]	new[177]|new[178]	_	_
26-43	4080-4086	longer	event[177]|time[178]	new[177]|new[178]	_	_
26-44	4087-4093	period	event[177]|time[178]	new[177]|new[178]	_	_
26-45	4094-4096	of	event[177]|time[178]	new[177]|new[178]	_	_
26-46	4097-4108	symptomatic	event[177]|time[178]|abstract[179]	new[177]|new[178]|giv[179]	_	_
26-47	4109-4116	benefit	event[177]|time[178]|abstract[179]	new[177]|new[178]|giv[179]	_	_
26-48	4117-4124	without	event[177]	new[177]	_	_
26-49	4125-4128	the	event[177]|abstract[180]	new[177]|new[180]	_	_
26-50	4129-4133	need	event[177]|abstract[180]	new[177]|new[180]	_	_
26-51	4134-4137	for	event[177]|abstract[180]	new[177]|new[180]	_	_
26-52	4138-4149	retreatment	event[177]|abstract[180]|event	new[177]|new[180]|giv	_	_
26-53	4150-4151	.	_	_	_	_

#Text=A previously published case series of 17 patients who received palliative radiotherapy for sarcoma using 39 Gy in 13 fractions over two and a half weeks demonstrated this was well tolerated and provided high rates of durable pain control .
27-1	4152-4153	A	abstract[183]	giv[183]	ana	27-28[0_183]
27-2	4154-4164	previously	abstract[183]	giv[183]	_	_
27-3	4165-4174	published	abstract[183]	giv[183]	_	_
27-4	4175-4179	case	person|abstract[183]	giv|giv[183]	_	_
27-5	4180-4186	series	abstract[183]	giv[183]	_	_
27-6	4187-4189	of	abstract[183]	giv[183]	_	_
27-7	4190-4192	17	abstract[183]|person[184]	giv[183]|giv[184]	coref	28-10[197_184]
27-8	4193-4201	patients	abstract[183]|person[184]	giv[183]|giv[184]	_	_
27-9	4202-4205	who	abstract[183]|person[184]	giv[183]|giv[184]	_	_
27-10	4206-4214	received	abstract[183]|person[184]	giv[183]|giv[184]	_	_
27-11	4215-4225	palliative	abstract[183]|person[184]|abstract[185]	giv[183]|giv[184]|giv[185]	coref	28-22[0_185]
27-12	4226-4238	radiotherapy	abstract[183]|person[184]|abstract[185]	giv[183]|giv[184]|giv[185]	_	_
27-13	4239-4242	for	abstract[183]|person[184]|abstract[185]	giv[183]|giv[184]|giv[185]	_	_
27-14	4243-4250	sarcoma	abstract[183]|person[184]|abstract[185]|substance	giv[183]|giv[184]|giv[185]|giv	coref	32-16
27-15	4251-4256	using	_	_	_	_
27-16	4257-4259	39	abstract[187]	new[187]	_	_
27-17	4260-4262	Gy	abstract[187]	new[187]	_	_
27-18	4263-4265	in	abstract[187]	new[187]	_	_
27-19	4266-4268	13	abstract[187]|abstract[188]	new[187]|new[188]	_	_
27-20	4269-4278	fractions	abstract[187]|abstract[188]	new[187]|new[188]	_	_
27-21	4279-4283	over	_	_	_	_
27-22	4284-4287	two	time[189]	new[189]	_	_
27-23	4288-4291	and	time[189]	new[189]	_	_
27-24	4292-4293	a	time[189]	new[189]	_	_
27-25	4294-4298	half	time[189]	new[189]	_	_
27-26	4299-4304	weeks	time[189]	new[189]	_	_
27-27	4305-4317	demonstrated	_	_	_	_
27-28	4318-4322	this	abstract	giv	_	_
27-29	4323-4326	was	_	_	_	_
27-30	4327-4331	well	_	_	_	_
27-31	4332-4341	tolerated	_	_	_	_
27-32	4342-4345	and	_	_	_	_
27-33	4346-4354	provided	_	_	_	_
27-34	4355-4359	high	abstract[191]	new[191]	_	_
27-35	4360-4365	rates	abstract[191]	new[191]	_	_
27-36	4366-4368	of	abstract[191]	new[191]	_	_
27-37	4369-4376	durable	abstract[191]|abstract[193]	new[191]|new[193]	_	_
27-38	4377-4381	pain	abstract[191]|abstract|abstract[193]	new[191]|giv|new[193]	_	_
27-39	4382-4389	control	abstract[191]|abstract[193]	new[191]|new[193]	_	_
27-40	4390-4391	.	_	_	_	_

#Text=Collection of survival data may help to assess if the correct patients are being offered higher dose , longer courses of radiotherapy .
28-1	4392-4402	Collection	abstract[194]	new[194]	_	_
28-2	4403-4405	of	abstract[194]	new[194]	_	_
28-3	4406-4414	survival	abstract[194]|event|abstract[196]	new[194]|new|new[196]	coref|coref	30-17[205_0]|31-3[207_196]
28-4	4415-4419	data	abstract[194]|abstract[196]	new[194]|new[196]	_	_
28-5	4420-4423	may	_	_	_	_
28-6	4424-4428	help	_	_	_	_
28-7	4429-4431	to	_	_	_	_
28-8	4432-4438	assess	_	_	_	_
28-9	4439-4441	if	_	_	_	_
28-10	4442-4445	the	person[197]	giv[197]	coref	31-26[212_197]
28-11	4446-4453	correct	person[197]	giv[197]	_	_
28-12	4454-4462	patients	person[197]	giv[197]	_	_
28-13	4463-4466	are	_	_	_	_
28-14	4467-4472	being	_	_	_	_
28-15	4473-4480	offered	_	_	_	_
28-16	4481-4487	higher	abstract[198]|place[199]	giv[198]|new[199]	coref	31-30[0_198]
28-17	4488-4492	dose	abstract[198]|place[199]	giv[198]|new[199]	_	_
28-18	4493-4494	,	place[199]	new[199]	_	_
28-19	4495-4501	longer	place[199]	new[199]	_	_
28-20	4502-4509	courses	place[199]	new[199]	_	_
28-21	4510-4512	of	place[199]	new[199]	_	_
28-22	4513-4525	radiotherapy	place[199]|abstract	new[199]|giv	coref	30-13[204_0]
28-23	4526-4527	.	_	_	_	_

#Text=Figure 4
29-1	4528-4534	Figure	abstract[201]	new[201]	_	_
29-2	4535-4536	4	abstract[201]	new[201]	_	_

#Text=however does not appear to show any correlation between the BED of the radiotherapy delivered and overall survival .
30-1	4537-4544	however	_	_	_	_
30-2	4545-4549	does	_	_	_	_
30-3	4550-4553	not	_	_	_	_
30-4	4554-4560	appear	_	_	_	_
30-5	4561-4563	to	_	_	_	_
30-6	4564-4568	show	_	_	_	_
30-7	4569-4572	any	abstract[202]	new[202]	_	_
30-8	4573-4584	correlation	abstract[202]	new[202]	_	_
30-9	4585-4592	between	abstract[202]	new[202]	_	_
30-10	4593-4596	the	abstract[202]|abstract[203]	new[202]|new[203]	_	_
30-11	4597-4600	BED	abstract[202]|abstract[203]	new[202]|new[203]	_	_
30-12	4601-4603	of	abstract[202]|abstract[203]	new[202]|new[203]	_	_
30-13	4604-4607	the	abstract[202]|abstract[203]|abstract[204]	new[202]|new[203]|giv[204]	_	_
30-14	4608-4620	radiotherapy	abstract[202]|abstract[203]|abstract[204]	new[202]|new[203]|giv[204]	_	_
30-15	4621-4630	delivered	abstract[202]|abstract[203]|abstract[204]	new[202]|new[203]|giv[204]	_	_
30-16	4631-4634	and	_	_	_	_
30-17	4635-4642	overall	event[205]	giv[205]	_	_
30-18	4643-4651	survival	event[205]	giv[205]	_	_
30-19	4652-4653	.	_	_	_	_

#Text=Interpretation of this data is extremely limited because of the heterogeneity of the patient population with multiple different histological subtypes and the small numbers of patients treated with each dose and fractionation schedule .
31-1	4654-4668	Interpretation	abstract[206]	new[206]	_	_
31-2	4669-4671	of	abstract[206]	new[206]	_	_
31-3	4672-4676	this	abstract[206]|abstract[207]	new[206]|giv[207]	_	_
31-4	4677-4681	data	abstract[206]|abstract[207]	new[206]|giv[207]	_	_
31-5	4682-4684	is	_	_	_	_
31-6	4685-4694	extremely	_	_	_	_
31-7	4695-4702	limited	_	_	_	_
31-8	4703-4710	because	_	_	_	_
31-9	4711-4713	of	_	_	_	_
31-10	4714-4717	the	abstract[208]	new[208]	_	_
31-11	4718-4731	heterogeneity	abstract[208]	new[208]	_	_
31-12	4732-4734	of	abstract[208]	new[208]	_	_
31-13	4735-4738	the	abstract[208]|person[209]	new[208]|new[209]	_	_
31-14	4739-4746	patient	abstract[208]|person[209]	new[208]|new[209]	_	_
31-15	4747-4757	population	abstract[208]|person[209]	new[208]|new[209]	_	_
31-16	4758-4762	with	abstract[208]|person[209]	new[208]|new[209]	_	_
31-17	4763-4771	multiple	abstract[208]|person[209]|abstract[210]	new[208]|new[209]|new[210]	coref	32-15[221_210]
31-18	4772-4781	different	abstract[208]|person[209]|abstract[210]	new[208]|new[209]|new[210]	_	_
31-19	4782-4794	histological	abstract[208]|person[209]|abstract[210]	new[208]|new[209]|new[210]	_	_
31-20	4795-4803	subtypes	abstract[208]|person[209]|abstract[210]	new[208]|new[209]|new[210]	_	_
31-21	4804-4807	and	_	_	_	_
31-22	4808-4811	the	abstract[211]	new[211]	_	_
31-23	4812-4817	small	abstract[211]	new[211]	_	_
31-24	4818-4825	numbers	abstract[211]	new[211]	_	_
31-25	4826-4828	of	abstract[211]	new[211]	_	_
31-26	4829-4837	patients	abstract[211]|person[212]	new[211]|giv[212]	_	_
31-27	4838-4845	treated	abstract[211]|person[212]	new[211]|giv[212]	_	_
31-28	4846-4850	with	abstract[211]|person[212]	new[211]|giv[212]	_	_
31-29	4851-4855	each	abstract[211]|person[212]|abstract[215]	new[211]|giv[212]|new[215]	_	_
31-30	4856-4860	dose	abstract[211]|person[212]|abstract|abstract[215]	new[211]|giv[212]|giv|new[215]	coref	32-8[217_0]
31-31	4861-4864	and	abstract[211]|person[212]|abstract[215]	new[211]|giv[212]|new[215]	_	_
31-32	4865-4878	fractionation	abstract[211]|person[212]|object|abstract[215]	new[211]|giv[212]|giv|new[215]	coref	32-12
31-33	4879-4887	schedule	abstract[211]|person[212]|abstract[215]	new[211]|giv[212]|new[215]	_	_
31-34	4888-4889	.	_	_	_	_

#Text=To gain a better understanding of the most appropriate dose and fractionation schedules for different sarcoma subtypes
32-1	4890-4892	To	_	_	_	_
32-2	4893-4897	gain	_	_	_	_
32-3	4898-4899	a	abstract[216]	new[216]	_	_
32-4	4900-4906	better	abstract[216]	new[216]	_	_
32-5	4907-4920	understanding	abstract[216]	new[216]	_	_
32-6	4921-4923	of	abstract[216]	new[216]	_	_
32-7	4924-4927	the	abstract[216]|abstract[219]	new[216]|giv[219]	coref	33-16[229_219]
32-8	4928-4932	most	abstract[216]|abstract[217]|abstract[219]	new[216]|giv[217]|giv[219]	coref	33-17[0_217]
32-9	4933-4944	appropriate	abstract[216]|abstract[217]|abstract[219]	new[216]|giv[217]|giv[219]	_	_
32-10	4945-4949	dose	abstract[216]|abstract[217]|abstract[219]	new[216]|giv[217]|giv[219]	_	_
32-11	4950-4953	and	abstract[216]|abstract[219]	new[216]|giv[219]	_	_
32-12	4954-4967	fractionation	abstract[216]|object|abstract[219]	new[216]|giv|giv[219]	coref	33-19
32-13	4968-4977	schedules	abstract[216]|abstract[219]	new[216]|giv[219]	_	_
32-14	4978-4981	for	abstract[216]|abstract[219]	new[216]|giv[219]	_	_
32-15	4982-4991	different	abstract[216]|abstract[219]|abstract[221]	new[216]|giv[219]|giv[221]	_	_
32-16	4992-4999	sarcoma	abstract[216]|abstract[219]|substance|abstract[221]	new[216]|giv[219]|giv|giv[221]	_	_
32-17	5000-5008	subtypes	abstract[216]|abstract[219]|abstract[221]	new[216]|giv[219]|giv[221]	_	_

#Text=large volume , multicentre , prospective data collections is required using a small number of different dose and fractionation schedules , ideally those outlined by the Royal College of Radiologists ( Table 5 ) .
33-1	5009-5014	large	abstract[222]|abstract[225]	new[222]|new[225]	_	_
33-2	5015-5021	volume	abstract[222]|abstract[225]	new[222]|new[225]	_	_
33-3	5022-5023	,	abstract[225]	new[225]	_	_
33-4	5024-5035	multicentre	place|abstract[225]	new|new[225]	_	_
33-5	5036-5037	,	abstract[225]	new[225]	_	_
33-6	5038-5049	prospective	abstract[225]	new[225]	_	_
33-7	5050-5054	data	abstract|abstract[225]	new|new[225]	_	_
33-8	5055-5066	collections	abstract[225]	new[225]	_	_
33-9	5067-5069	is	_	_	_	_
33-10	5070-5078	required	_	_	_	_
33-11	5079-5084	using	_	_	_	_
33-12	5085-5086	a	abstract[226]	new[226]	_	_
33-13	5087-5092	small	abstract[226]	new[226]	_	_
33-14	5093-5099	number	abstract[226]	new[226]	_	_
33-15	5100-5102	of	abstract[226]	new[226]	_	_
33-16	5103-5112	different	abstract[226]|abstract[229]	new[226]|giv[229]	_	_
33-17	5113-5117	dose	abstract[226]|abstract|abstract[229]	new[226]|giv|giv[229]	_	_
33-18	5118-5121	and	abstract[226]|abstract[229]	new[226]|giv[229]	_	_
33-19	5122-5135	fractionation	abstract[226]|object|abstract[229]	new[226]|giv|giv[229]	_	_
33-20	5136-5145	schedules	abstract[226]|abstract[229]	new[226]|giv[229]	_	_
33-21	5146-5147	,	_	_	_	_
33-22	5148-5155	ideally	_	_	_	_
33-23	5156-5161	those	_	_	_	_
33-24	5162-5170	outlined	_	_	_	_
33-25	5171-5173	by	_	_	_	_
33-26	5174-5177	the	organization[230]	new[230]	_	_
33-27	5178-5183	Royal	organization[230]	new[230]	_	_
33-28	5184-5191	College	organization[230]	new[230]	_	_
33-29	5192-5194	of	organization[230]	new[230]	_	_
33-30	5195-5207	Radiologists	organization[230]|abstract	new[230]|giv	_	_
33-31	5208-5209	(	_	_	_	_
33-32	5210-5215	Table	abstract[232]	new[232]	_	_
33-33	5216-5217	5	abstract[232]	new[232]	_	_
33-34	5218-5219	)	_	_	_	_
33-35	5220-5221	.	_	_	_	_
